JIJason P. Izard

Jason P. Izard

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jason P. Izard has a total of 89 co-authors. Here are the top co-authors by number of shared publications:

  • Jonathan L. Wright

    Department of Urology, University of Washington School of Medicine, Seattle, Washington

    9 shared publications
  • D. Robert Siemens

    Department of Urology, Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, Queen's University, Kingston, Canada; Department of Oncology, Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, Queen's University, Kingston, Canada; Queen's University Cancer Research Institute, Queen's University, Kingston, Canada

    7 shared publications
  • John L. Gore

    Department of Urology, University of Washington School of Medicine, Seattle, USA

    7 shared publications
  • D. Robert Siemens

    Department of Urology, Queen’s University, Kingston, Ontario, Canada

    5 shared publications
  • Daniel W. Lin

    Department of Urology, University of Washington School of Medicine, Seattle, WA

    4 shared publications
  • Evan Y. Yu

    Division of Oncology, Department of Medicine, University of Washington, Seattle, WA

    4 shared publications

Latest Publications

  • Re: Scientists Rise up Against Statistical Significance

    by Jason Izard, Yingwei Peng, D. Robert Siemens


  • Editorial Comment

    by Jason P. Izard, D. Robert Siemens

  • Depression and prostate cancer: A focused review for the clinician

    by Gagan Fervaha, Jason P. Izard, Dean A. Tripp, Selina Rajan, Darryl P. Leong, D. Robert Siemens


  • What’s in your toolkit? Guiding our patients through their shared decision-making

    by Jason Izard, D. Robert Siemens

    What’s in your toolkit? Guiding our patients through their shared decision-making

  • Temporal trends in management and outcomes of testicular cancer: A population‐based study

    by Michael J. Leveridge, D. Robert Siemens, Kelly Brennan, Jason P. Izard, Safiya Karim, Howard An, William J. Mackillop, Christopher M. Booth

    BACKGROUND: Treatment guidelines for early‐stage testicular cancer have increasingly recommended de‐escalation of therapy with surveillance strategies. This study was designed to describe temporal trends in routine clinical practice and to determine whether de‐escalation of therapy is associated with inferior survival in the general population.METHODS: The Ontario Cancer Registry was linked to electronic records of treatment to identify all patients diagnosed with testicular cancer treated with orchiectomy in Ontario during 2000‐2010. Treatment after orchiectomy was classified as radiotherapy (RT), retroperitoneal lymph node dissection (RPLND), chemotherapy, or none. Surveillance was defined as no identified treatment within 90 days of orchiectomy. Overall survival (OS) and cancer‐specific survival (CSS) were measured from the date of orchiectomy.RESULTS: The study population included 1564 and 1086 cases of seminomas and nonseminoma germ cell tumors (NSGCTs), respectively. Among patients with seminomas, there was a significant increase in the proportion of patients with no treatment within 90 days of orchiectomy (from 56% to 84%; P < .001); the use of RT decreased over time (from 38% to 8%; P < .001); and the use of chemotherapy remained stable (from 6% to 9%; P = .289). Practice patterns 90 days after orchiectomy remained stable over time among patients with NSGCTs: from 51% to 57% for no treatment (P = .435), from 43% to 43% for chemotherapy (P = .336), and from 9% to 3% for RPLND (P = .476). The OS rates for the entire cohort at 5 and 10 years were 97% and 96%, respectively; the CSS rates were 98% and 98%, respectively. There was no significant change in OS or CSS for patients with seminomas or NSGCTs during the study period.CONCLUSIONS: There has been substantial de‐escalation in the treatment of testicular cancer in routine practice since 2000. Long‐term survival in routine practice is excellent and has not decreased with the uptake of surveillance strategies. Cancer 2018;124:2724‐2732. © 2018 American Cancer Society


  • Open Access

    The emerging role of patient reported outcomes in urology

    by Jason P. Izard

    The emerging role of patient reported outcomes in urology


  • Open Access

    Partial cystectomy for urothelial carcinoma of the bladder: Practice patterns and outcomes in the general population

    by Michael J. Leveridge, D. Robert Siemens, Jason P. Izard, Xuejiao Wei, Christopher M. Booth

    Introduction: Partial cystectomy (PC) for urothelial carcinoma (UC) in selected patients may avoid the morbidity of radical cystectomy (RC). We describe use and outcomes of PC for UC in routine clinical practice.Methods: All patients with urothelial carcinoma of the bladder (UCB) undergoing PC or RC in Ontario from 1994‒2008 were identified using the Ontario Cancer Registry and linked electronic records. Pathology reports were reviewed. Variables associated with PC use were identified using logistic regression. Cox proportional hazards model identified factors affecting cancer-specific (CSS) and overall survival (OS).Results: A total of 3320 patients underwent PC (n=181; 5%) or RC (n=3139; 95%) from 1994‒2008. PC patients were older (36% 80+ years vs. 19%; p<0.001) and more likely to have organ-confined (&lh;pT3) disease (54% vs. 36% RC; p<0.001). Two-thirds (67%) of PC patients did not undergo lymph node dissection (24% for RC; p<0.001). Factors associated with having PC included older age (odds ratio [OR] 1.55; 95% confidence interval [CI] 0.96‒2.51 for 70+ years), moderate comorbidity (OR 1.95; 95% CI 1.13‒3.37), and surgery outside of a comprehensive cancer centre (OR 1.44; 95% CI 1.03‒2.01). Unadjusted five-year OS for PC and RC cases was 34% and 33%, respectively (p=0.455); CSS at five years was 43% and 37% (p=0.045). On adjusted analysis, PC was associated with comparable CSS (hazard ratio [HR] 0.87, 95% CI 0.70‒1.09) and OS (HR 0.95, 95% CI 0.79‒1.14) as RC.Conclusions: In routine clinical practice, PC is not common. A substantial proportion of patients treated with PC achieve longterm survival. PC remains a treatment option in selected patients with UCB.


  • Open Access

    Biopsychosocial impact of prostate cancer and androgen-deprivation therapy

    by Dean A. Tripp, Phylicia Verreault, Steven Tong, Jason Izard, Angela Black, D. Robert Siemens

    Introduction: Prostate cancer is the most non-cutaneous malignancy in men, and androgen-deprivation therapy (ADT) is a cornerstone of management in advanced disease. The aim of this study was to evaluate the association of ADT with changes in depression and mental and physical quality of life (QoL) within a prospective patient cohort design. Methods: Patients were prospectively recruited and consented at a single academic health sciences centre in Ontario, Canada. Inclusion criteria included those men with adenocarcinoma of the prostate and either on watchful waiting or initiating ADT as palliation or as an adjuvant therapy for high-risk localized disease. All three cohorts were followed in routine care and completed psychosocial evaluations, including depression, social support, anxiety, and QoL measures. Results: In comparison to the control cohort of patients with prostate cancer on watchful waiting, initiation of ADT over a two-year period of time was not associated with any changes in depression or mental QoL. Instead, all patients, regardless of treatment cohort, showed increased depression scores and reduced mental QoL scores over time; however, for patients receiving ADT, a significant reduction in physical QoL compared to patients who did not receive ADT was demonstrated. Conclusions: ADT does not appear to significantly impact depressive symptoms and mental QoL over a two-year period; however, the depressive symptoms in this limited sample of men with prostate cancer was higher than expected and monitoring for these may be advisable for those who care for such patients.


  • Patient-reported outcome measures in urology

    by Gopal L. Narang, Stephanie C. Pannell, Aaron A. Laviana, Kathy H.Y. Huen, Jason Izard, Angela B. Smith, Jonathan Bergman

    Many urologic treatments have similar clinical outcomes, necessitating alternative methods to discriminate between options. Patient-reported outcome measures (PROMs) have become the new standard for evaluating the patient experience, and their use has drastically increased over the past decade. The purpose of this review is to discuss the status of PROMs in urology, highlight commonly used tools and address their future direction. An increasing number of urology-specific PROMs tools have been developed and validated. An increased focus on patient-centered care has provided an impetus for their rise in use. Implementation of PROMs has transitioned from being primarily descriptive in nature to producing actionable findings. Many PROMs are now implemented in daily clinical practice. The future of PROMs will involve new instrument development, integration into clinical practice and the use of PROMs as performance measures. PROMs are effective tools for characterizing symptom burden and health-related quality of life. With increasing clinical implementation, PROMs are playing an increasing role in patients’ clinical decision-making.